Q-linea further expands US commercial team

Q-linea AB (publ) (OMX: QLINEA) today announces the appointment of a new corporate account manager in the US market

This appointment will provide additional coverage focused on the northeast US region which is home to many leading healthcare providers and medical technology pioneers. Q-linea has made four new hires into its US commercial team in recent months following FDA approval of its flagship ASTar rapid AST system.

"We are very excited to be building a team of experienced industry leaders who can help to bring our novel technology to laboratories and patients across the US. We have seen a notable increase in our pipeline of interested customers since FDA clearance in April and this additional resource will facilitate our aim to place our first commercial ASTar instruments in the US during Q4 2024 and continue to deliver on our plan during the first half of 2025", says Jim Kathrein, VP US Commercial Operations.

Q-linea is a market leader in rapid antimicrobial susceptibility testing (rAST) and received FDA approval in April 2024 for its blood culture Gram-negative panel on the ASTar diagnostic instrument. It is to date the only rAST platform to receive dedicated New Technology Add-on Payment (NTAP) reimbursement funding from the US CMS.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-07 14:32 CEST.

Attachments

Q-linea further expands US commercial team